Ipsen’s Global Research and Development Pipeline (as of January 29, 2015)

  Phase I Phase II Phase III
Oncology and Endocrinology

TRIPTORELIN (EX-US)

Combined hormonal therapy for premenopausal breast cancer
Yes Yes Yes

TRIPTORELIN (EX-US)

Evaluation of the efficacy of the 3-month pamoate subcutaneous formulation
Yes Yes Yes

TASQUINIMOD (EX-US)

Metastatic castration-resistant prostate cancer (with Active Biotech)
Ipsen is a partner to co-develop tasquinimod
Ipsen has rights to tasquinimod worldwide except North America, South America, and Japan
Status in April 2014: This study is ongoing, but not recruiting patients
Yes Yes Yes

TASQUINIMOD (EX-US)

Hepatocellular, ovarian, renal cell, and gastric cancers
Yes Yes  

TASQUINIMOD (EX-US)

Maintenance therapy after chemotherapy in prostate cancer
Active Biotech is a partner to co-develop tasquinimod
Ipsen has rights to tasquinimod worldwide except North America, South America, and Japan
Status in April 2014: This study is recruiting patients
Yes Yes  
Neurology

BN82451

Huntington’s disease symptoms
Yes Yes  

AbobotulinumtoxinA

Muscle spasticity of lower limbs in adults
Yes Yes Yes

AbobotulinumtoxinA

Muscle spasticity of upper limbs in adults
Yes Yes Yes

AbobotulinumtoxinA

Muscle spasticity of lower limbs in children
Yes Yes Yes

AbobotulinumtoxinA

Muscle spasticity of upper limbs in children
Yes Yes Yes

AbobotulinumtoxinA

Neurogenic detrusor overactivity
Yes Yes  

AbobotulinumtoxinA

Temporary correction of moderate to severe glabellar lines in adults (China)
Yes Yes  

All compounds are investigational only; research is underway to evaluate safety and efficacy in these potential therapeutic areas.